Lung cancer combination results, ovarian cancer evidence and early prostate cancer research.
Oncology research
Imdelltra combination extends survival in small cell lung cancer trial
A Phase III trial found that Imdelltra plus Imfinzi extended median survival to 21.1 months versus 12.7 months with Imfinzi alone in extensive-stage small cell lung cancer. Serious side effects occurred in 20.9% versus 10.8%; the results support potential earlier use but do not constitute approval for this combination.
Why it matters: Offers substantial survival evidence in an aggressive cancer, alongside increased toxicity requiring careful assessment.
Genmab reports Phase III survival benefit for ovarian cancer candidate
Genmab announced that investigational Rina-S improved progression-free and overall survival versus chemotherapy in platinum-resistant ovarian cancer. The company reported a 71% relative reduction in progression or death in the overall trial population, with no new safety signals; detailed results and regulatory discussions are still forthcoming.
Why it matters: Adds promising late-stage evidence for an antibody-drug conjugate in a setting with limited treatment options, pending fuller scrutiny.
Experimental oral prostate cancer drug shows early activity
Johnson & Johnson reported tumour responses with JNJ-6143 in heavily pretreated advanced prostate cancer. At the 50-mg dose, 77% of 31 evaluable patients had PSA reductions of at least 50%; common adverse effects included nausea and elevated blood lipids, and larger studies remain necessary.
Why it matters: Introduces an early clinical signal for a new treatment mechanism, with efficacy, durability and safety still requiring confirmation.
Editorial summaries for general information only; not medical advice. Research findings and company announcements should be read in their original context.